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Scientiﬁc effort focused on the characterization
of the mechanisms of arsenic-induced human
toxicity is currently proceeding along several
lines of research, including characterization of
the spectrum of disease manifestations in
human arsenicism, discovery of the proximal
biochemical targets of arsenic toxicity, and the
elucidation of the gene products involved
in the complex biotransformation of arsenic
(Karagas et al. 2004; Thomas et al. 2004).
Understanding the biotransformation of
arsenic is essential to a complete understanding
of human arsenicism—a point that is under-
scored by the wealth of arsenic toxicology liter-
ature suggesting that the various chemical
forms of arsenic in the human biotransforma-
tion scheme can have markedly different toxic
potencies and spectra of biologic targets (Mass
et al. 2001; Styblo et al. 2000, 2002). This
relationship between the production and clear-
ance of various chemical forms of arsenic and
the particular manifestation of arsenic toxicity
in humans could explain both the variability
in measured phenotypes relating to arsenic
metabolism in exposed human populations
and the long-standing observation of indi-
vidual variability in arsenic toxicity among
relatively homogeneously exposed human
populations (Rahman et al. 2003; Watanabe
et al. 2001). If the metabolism of arsenic fol-
lows similar parameters as the metabolism of a
number of xenobiotics, genetic variation in
metabolic pathway members could be a deter-
minant of individual variation in metabolism
and concomitant toxicity (Hein et al. 1992;
May 1994). For some time now hypotheses
have been advanced that invoke genetic deter-
minants of individual variability in arsenic
metabolism, based on the observed variation in
urinary arsenic metabolic proﬁles in humans,
and on interspecies and intraspecies strain dif-
ferences in animal models (Styblo et al. 1999;
Thomas et al. 2001; Vahter 2000). More
recently, the case for genetic determinants of
variability in human arsenic metabolism was
strengthened by Chung et al. (2002), who
found a stronger correlation in arsenic methy-
lation-related phenotypes among siblings than
among genetically unrelated individuals.
To date, the arsenic literature speciﬁcally
supports three genes as being involved in
arsenic biotransformation: purine nucleoside
phosphorylase (PNP), glutathione-S-transferase
omega (GSTO), and arsenic(III) methyltrans-
ferase (CYT19) (Lin et al. 2002; Radabaugh
et al. 2002; Zakharyan et al. 2001). (Recently
the HUGO-recognized name for CYT19 has
been designated AS3MT.) Some but not all
reports show that PNP is capable of function-
ing in the reduction of arsenate to arsenite
(Nemeti et al. 2003; Radabaugh et al. 2002).
GSTO is capable of the reduction of mono-
methylarsenic(V) [MMA(V)] to monomethyl-
arsenic(III) (Nemeti and Gregus 2004).
CYT19 was initially characterized as an arsenic
methyltransferase in rodents that is capable of
the methylation of inorganic arsenic to its
monomethyl form, and of monomethylarsenic
to its dimethylarsenic form (Lin et al. 2002). In
rodents, CYT19, in the presence of the proper
system of reducing equivalents, has been pro-
posed to be capable of the entire gamut of
arsenic biotransformations that begin with
arsenite and end with dimethylarsenic(V)
[DMA(V)] (Thomas et al. 2004). These studies
have provided the identity of candidate genes
and the basis for beginning the genetic asso-
ciation studies necessary to test the hypotheses
of the existence of genetic determinants of
interindividual variability of arsenic metabo-
lism. A second prerequisite for genetic associa-
tion studies is a catalog of the variable positions
within the candidate genes, preferably ascer-
tained in an ethnically relevant population.
Collectively, several studies have produced
these catalogs in various ethnic populations for
GSTO (Marnell et al. 2003; Whitbread et al.
2003; Yu et al. 2003). In addition, catalogs of
polymorphic sites in PNP have been published
for European and indigenous Americans (Yu
et al. 2003). Despite the availability of these
catalogs, only one genetic association study has
been reported (Marnell et al. 2003).
To address the need for genetic association
studies aimed at testing the hypothesis of the
existence of genetic determinants of interindi-
vidual variability in human arsenic metabo-
lism, we used existing polymorphism catalogs
for GSTO and PNP, produced a resequencing-
derived catalog of polymorphisms in CYT19
(no such resequencing-based catalog was pub-
licly available), and tested 23 polymorphic sites
within these three genes in a population of
arsenic-exposed subjects from the Yaqui Valley
area of Sonora, Mexico, who had been pheno-
typed for the levels of urinary metabolites of
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We report the results of a screen for genetic association with urinary arsenic metabolite levels in
three arsenic metabolism candidate genes, PNP, GSTO, and CYT19, in 135 arsenic-exposed sub-
jects from the Yaqui Valley in Sonora, Mexico, who were exposed to drinking water concentra-
tions ranging from 5.5 to 43.3 ppb. We chose 23 polymorphic sites to test in the arsenic-exposed
population. Initial phenotypes evaluated included the ratio of urinary inorganic arsenic(III) to
inorganic arsenic(V) and the ratio of urinary dimethylarsenic(V) to monomethylarsenic(V) (D:M).
In the initial association screening, three polymorphic sites in the CYT19 gene were signiﬁcantly
associated with D:M ratios in the total population. Subsequent analysis of this association revealed
that the association signal for the entire population was actually caused by an extremely strong
association in only the children (7–11 years of age) between CYT19 genotype and D:M levels.
With children removed from the analysis, no signiﬁcant genetic association was observed in adults
(18–79 years). The existence of a strong, developmentally regulated genetic association between
CYT19 and arsenic metabolism carries import for both arsenic pharmacogenetics and arsenic toxi-
cology, as well as for public health and governmental regulatory officials. Key words: arsenic
metabolism, CYT19, genetic association, GSTO, pharmacogenetics, PNP, polymorphism, SNP.
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[Online 22 March 2005]arsenic. We performed subsequent genetic
association analysis to screen for the presence
of statistically signiﬁcant effects of genotypes
on arsenic metabolism, as indirectly reﬂected
by urinary arsenic metabolite levels.
Materials and Methods
Description of study subjects. A total of 144
subjects were included in the study, ranging in
age from 7 to 79 years, from several towns in
the Yaqui Valley of Sonora, Mexico. Subjects
were recruited in 2004 by contact through
local health care officials, after attending an
informational meeting in their hometowns.
All subjects were in good health (self-reported
and by physical examination) and free from
any skin lesions suggestive of arsenic toxicity.
Although we did not track the characteristics
of individuals who declined to be in the study,
participation rate was estimated to be > 90%
of the individuals who attended the informa-
tional meetings. Before field collection, we
decided to collect two age groups, an adult
group ≥ 18 years of age and a child group
between 7 and 11 years of age, with the lower
age limit based on the logistics of sample
collection and the upper age limit chosen to
avoid confounding effects of puberty in the
child group. The towns (and arsenic content
of their drinking water) were Esperanza (each
of two wells measured multiple times; com-
bined mean ± SD, 43.3 ± 8.4 µg As/L),
Cocorit (one well, 19.33 ± 0.8 µg As/L),
Pueblo Yaqui (two wells, combined mean,
9.65 ± 0.23 µg As/L), Colonia Allende (one
well, 5.5 ± 0.20 µg As/L), and Campo 47 (one
well, 5.5 ± 0.07 µg As/L). Subjects reported
that their sole source of drinking water was
well water, although we did not independently
validate this. Of the study population, 86 indi-
viduals were unrelated to any other study par-
ticipants, 36 subjects consisted of duos of one
parent and one child of that parent, 9 subjects
consisted of trios of one parent and two chil-
dren, 9 subjects consisted of trios of two parents
and one child, and 4 subjects consisted of pairs
of siblings. All subjects gave their informed con-
sent, as approved by the Human Subjects
Committee of the University of Arizona and
the Ministry of Public Health of Sonora State.
Participants were asked to exclude seafood from
their diet for 3 days before sample collection.
Physical data and data on health status, ciga-
rette smoking, dietary habits, and other vari-
ables were obtained by questionnaire and
physical examination. Subjects agreed to donate
peripheral blood or buccal cells and urine sam-
ples for DNA isolation and arsenic determina-
tion, respectively. We failed to collect urine or
tissue from five subjects, resulting in a total
usable study population of 139 individuals.
Tissue collection: blood samples. Blood was
collected by venous puncture. Personnel from
the Ministry of Public Health withdrew 5 mL
of blood from each subject into Vacutainers
containing anticoagulant. The samples were
transported on ice to the Sonora Institute of
Technology, where they were kept at 4°C for
up to 3 days before the DNA extraction was
performed.
Tissue collection: buccal samples. Subjects
vigorously rinsed their mouth twice, each time
with 25 mL commercial mouthwash, and then
discharged the rinse into a 50 mL conical tube.
The tubes were stored at 4°C until the DNA
extraction was performed.
DNA isolation: blood samples. Genomic
DNA was extracted from whole blood samples
using the Blood and Cell Culture Midi Kit
(QIAGEN, Valencia, CA, USA).
DNA isolation: buccal samples. Tubes
containing buccal cells were centrifuged at
4,200 rpm for 10 min, washed with sodium
chloride solution, and centrifuged again at
4,200 rpm for 10 min. The cell pellet was
then processed for DNA isolation using the
QIAamp Mini kit (QIAGEN).
Urine collection. First morning void urine
samples were obtained in 100-mL polypro-
pylene bottles and kept on ice. Within 6 hr,
cooled samples were taken to the Sonora
Institute of Technology and kept frozen at
–40°C. The accumulated samples were then
shipped on dry ice to the University of Ari-
zona, where the samples were stored at –80°C
until the analysis was performed.
Total arsenic analysis. Urine samples were
digested with nitric acid using a microwave
oven, following published protocols (Fran-
cesconi et al. 2002). Freeze-dried urine refer-
ence material for trace elements (Clinchek-
control; RECIPE, Munich, Germany), con-
taining arsenic at a level of 68 µg As/L, was
used for quality control and to validate the
assay. Analysis of this standard by inductively
coupled plasma/mass spectrometry (ICP/MS)
yielded a range of 64.6–68.9 µg As/L with a
range of recoveries of 94.9–101.3%.
Arsenic speciation analysis. Frozen samples
were thawed at room temperature and diluted
2-fold using Milli-Q water and ﬁltered with a
0.45 µm ﬁlter before injection (Mandal et al.
2001). The HPLC system consisted of an
Agilent 1100 HPLC with a reverse-phase
C18 column (Prodigy 3 µm ODS, 150 ×
4.60 mm2; Phenomenex, Torrance, CA,
USA), with an Agilent 7500 ICP/MS used as
a detector for the analysis of arsenic species
{(arsenic(III) [As(III)], arsenic(V) [As(V)],
MMA(V), and DMA(V)}. The detection lim-
its, quality control, precision, and accuracy of
this analytical method were assessed. The
detection limits were 0.42–1.08 µg/L for
arsenic compounds. The precision was esti-
mated 10 times with a solution containing
approximately 10 times the detection limit
concentrations, yielding percentages of relative
standard deviation of 1.14–4.00%. Accuracy
values were calculated by spiking standard
compounds of all the species that were studied
[10 µg/L As(III), As(V), and MMA(V);
20 µg/L DMA(V)] in urine samples. The
recovery of the added compounds was
96–108%. Similar recovery experiments used
reference urine samples (Institut National de
Santéé Publique Québec, Québec, Canada),
containing As(III), MMA(V), and DMA(V).
Analyses of these standards yielded recoveries
between 80 and 109%.
Resequencing: resequencing subjects.
Anonymous DNA samples from healthy indi-
viduals of self-reported ancestry were obtained
from the Coriell Institute (Camden, NJ, USA).
We studied 22 samples from individuals of
European ancestry (EA), and 24 samples from
individuals of indigenous American ancestry
(IA). EA individuals were selected from unre-
lated Centre d’Etudes du Polymorphisme
Humain (CEPH; Paris, France) samples. The
geographic origin of the IA samples consisted
of ﬁve samples from Peru, nine samples from
Mexico, one sample from Ecuador, and nine
samples from Brazil. One DNA sample iso-
lated from a chimpanzee was also included in
the study. These samples are commercially
available; sample identification and ordering
information are available from the authors.
Resequencing: PCR amplification.
Genomic sequence for CYT19 was accessed
from the Human Genome Browser (University
of California, Santa Cruz 2004). Because of
the large genomic size of human CYT19, we
used a sampling strategy in determining the
subset of the 32.4-kilobase (kb) genomic
region to resequence. Included in the rese-
quencing were approximately 2 kb 5´ to the
ﬁrst exon, 1 kb 3´ to the last exon, all exons,
including at least 100 bases of the exon intron
junction, and roughly evenly spaced regions of
intron sequence. Within this strategy a total
of 12.2 kb of the genomic region were rese-
quenced. Polymerase chain reaction (PCR)
amplicons were designed such that each ampli-
con was approximately 900 base pairs (bp) in
length, and consecutive amplicons overlapped
each other by approximately 200 bp. PCR
reactions contained 20 ng genomic DNA,
1 pmol of each primer, 0.2 U Taq polymerase
(platinum Taq; Invitrogen, Carlsbad, CA,
USA), and 0.1 µM dNTPs in a total volume
of 10 µL. Speciﬁc reaction conditions, includ-
ing primer sequences, are available from the
authors.
Resequencing: direct PCR sequencing.
PCR amplicons were prepared for cycle
sequencing by diluting them with water using
a dilution range of 1:3 to 1:6, depending on
the reaction yield, as determined by agarose
gel electrophoresis. Cycle sequencing reac-
tions were assembled using 0.4 µL of cycle
sequencing premix (BigDye V3.0; Applied
Biosystems, Foster City, CA, USA), 1 pmol
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dilution buffer and 5 µL of PCR product in a
ﬁnal volume of 10 µL. Cycle sequencing reac-
tions were puriﬁed using DNA-afﬁnity mag-
netic beads (Agencourt Biosciences, Beverly,
MA, USA). Purified sequencing reactions
were electrophoretically analyzed using a
DNA Analyzer 3730xl (Applied Biosystems).
Resequencing: polymorphism identiﬁcation
and analysis. Sequence chromatograms were
processed for base calling and assembly using
the Phred, Phrap and Consed suite of software
programs (Ewing et al. 1998; Gordon et al.
1998). Initial polymorphism tagging was per-
formed using Polyphred, with a minimum
sequence quality of phred 25 (Nickerson et al.
1997). Potential polymorphic sites that were
initially identiﬁed by Polyphred were individu-
ally conﬁrmed by visual inspection of sequence
traces. A criterion of this visual inspection–
conﬁrmation was that the polymorphism must
have been observed in multiple chromatograms
from singleton polymorphisms (polymor-
phisms occurring in only one subject) or in
multiple subjects. For these confirmed poly-
morphic sites, each genotype for each subject
was also confirmed by visual inspection of
chromatograms. Polymorphic sites and associ-
ated subject-identified genotypes were auto-
matically output to a relational database for
further analysis, which included the automated
generation of ethnicity-speciﬁc genotype fre-
quencies, allele frequencies, and goodness-
of-fit tests for Hardy-Weinberg equilibrium.
Haplotypes were inferred using a Gibbs-
sampling algorithm as implemented in the
PHASE software program (Stephens and
Donnelly 2003; Stephens et al. 2001). Because
the accuracy of statistically inferred haplotypes
has been shown to increase with increasing hap-
lotype frequency, we used polymorphisms with
a minimum frequency (minor allele frequency;
MAF) of 0.10 to define relatively common
haplotypes (Tishkoff et al. 2000). Pairwise link-
age disequilibrium (LD) was calculated as r2, a
measure of the product-moment correlation
coefﬁcient (Devlin and Risch 1995).
Resequencing: annotation of polymorphic
sites. Each gene was annotated graphically using
the Artemis software program (Rutherford et al.
2000). Annotations included exon location,
protein coding exon subset, reading frame,
and polymorphism site. Coding region poly-
morphisms were evaluated for codon changes
resulting from polymorphisms and the pre-
dicted effect on amino acid sequence.
Genotyping: selection of polymorphic sites
for genetic association analysis. From the
ethnicity-speciﬁc catalogs of polymorphic sites,
a tagging strategy based on bins of polymorphic
sites that exceeded 10% minor allele frequency
and a within-bin LD (r2) exceeding 0.7 was
employed, using publicly available software
as recently described (Carlson et al. 2004).
Because we did not know in advance the extent
to which the population from Sonora would be
accurately modeled in polymorphic site fre-
quency and in LD by the EA and IA resequenc-
ing populations, tagging polymorphisms were
ascertained independently in the IA and the EA
populations. Tagging sites that were shared by
the EA and IA groups were identiﬁed wherever
possible; however, one tagging site for each bin
for each group was included in the ﬁnal analy-
sis. Some nonsynonymous polymorphic sites at
< 10% frequency were combined with the set
of bin-tagging sites to be used in association
testing.
Genotyping: Taqman genotyping. All poly-
morphic sites selected for genetic association
testing were submitted for assay development
to the “Assay by Design” service (Applied
Biosystems). Sites that were successfully devel-
oped through this system were genotyped
using the 5´-exonuclease–based Taqman assay.
Reaction mixtures, consisting of 1× Taqman
universal PCR master mix, 1× assay reagent
(Applied Biosystems), and template (genomic
DNA at 15 ng or water blank) were robotically
assembled. Total reaction volume was 5 µL.
Plates were sealed with optical sealing ﬁlm and
subjected to thermal cycling in PCR 9700
thermal cyclers (Applied Biosystems) at 95°C
for 15 min, followed by 40 cycles of 92°C for
15 sec and 60°C for 1 min. Following thermal-
cycling, plates were assayed for fluorescence
using a 7900HT sequence detection system
(Applied Biosystems). Assignment of geno-
types was based on the ratio of reporter ﬂuores-
cence to passive dye standard and performed
automatically using the “auto-clustering” fea-
ture of the allelic discrimination software
(SDS, version 2.0; Applied Biosystems).
Genotyping: sequencing-based genotyping.
Polymorphic sites that could not be success-
fully designed into Taqman assays were geno-
typed by conventional DNA resequencing, as
described above. Trained analysts scored chro-
matograms from each subject at the polymor-
phic site for the three possible genotypes.
Genotyping: quality control. The 22 EA
samples used in the initial resequencing that
produced the polymorphism catalogs were
included in all genotyping samples sets, includ-
ing Taqman and resequencing-based genotyp-
ing. Genotyping results from Taqman assays in
the 22 EA DNA samples were compared with
genotypes that were derived from resequencing
in the same samples. Resequencing-based geno-
typing included the 22 EA subjects that were
included in the original resequencing project in
which the polymorphism was ﬁrst identiﬁed.
Deviation from Hardy-Weinberg equilibrium
at each site was tested using goodness of ﬁt chi-
square or Fisher exact test. Nonassignment rates
were also calculated at each site tested.
Statistical analyses. All statistical analyses
were performed using SPSS software (version
12; SPSS, Chicago, IL, USA). Evaluation of
the polymorphisms for genetic association with
urinary arsenic metabolites involved calculating
three derivative phenotypes: the ratio of inor-
ganic As(III) to inorganic As(V) (3:5), the ratio
of DMA(V) to MMA(V) (D:M), and the ratio
of inorganic As(III) to MMA(V) (3:M). All
three variables were transformed by a natural
log conversion to approximate a normal dis-
tribution. Two of the phenotypes, 3:5 and
D:M, were used in the initial screen for genetic
association between each variable and each
polymorphic site. Genotypes were recoded to
conform to an analysis of a dominant genetic
effect, in which the major homozygotes were
assigned one categorical variable value and a
second categorical variable value was assigned
to the combined heterozygotes and minor
homozygotes. For a given phenotype, mean
values of each genotypic group were tested for
difference using t-tests (two-tailed) for variables
that did not deviate signiﬁcantly from a normal
distribution. Mann-Whitney and Wilcoxon
tests were used to compare the means of vari-
ables that demonstrated a signiﬁcant (p < 0.05)
departure from a normal distribution, based
on Kolmogorov-Smirnov or Shapiro-Wilk
tests. The initial genetic association screening
involved testing 23 polymorphic sites in two
variables. To correct for multiple testing, a
Bonferroni correction was applied to adjust
each level of significance value for 46 tests.
Because the presence of closely related subjects
violates the assumption of the independence of
samples, parents of the children that were ana-
lyzed in this study as well as one randomly
selected member of each of the five sibling
pairs in the study were removed from the sta-
tistical tests for difference of means between
genotype groups.
We evaluated the relationship between
other factors such as age, sex, daily arsenic dose
(estimated by the product of arsenic well water
concentration by self-reported average daily
water consumption volume divided by body
weight), and D:M ratio using a stepwise linear
regression model, with log-transformed D:M
ratio as the dependent variable and genotype,
age, sex, and log-transformed daily arsenic
dose as independent variables. The entry and
removal criteria of the model were probabilities
of F-values < 0.05 for entry and > 0.10 for
removal. We evaluated the difference between
genotype effects in adults versus children using
a general linear model in a univariate analysis
that included log D:M ratio as the dependent
variable, with genotype and child/adult status
as fixed factors, together with an interaction
term for these two factors.
Results
Resequencing of CYT19. In total, 12.2 kb of
the genomic region that includes CYT19 were
resequenced. The polymorphic sites discovered
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contexts are displayed graphically in Figure 1.
We have previously published the resequencing
results for GSTO and PNP (Yu et al. 2003).
The consensus sequence and the location and
sequence context of all polymorphic sites in
PNP, CYT19, and GSTO have been submitted
to Genbank (accession numbers AY817667,
AY817668, and AY817669, respectively) and
to dbSNP (www.ncbi.nlm.nih.gov/SNP, sub-
mitter handle KLIMECKI_LAB). Because the
northern Mexican population represents an
admixture between IA and EA, resequencing in
all genes was done in separate EA and IA pop-
ulations, to obtain the largest set of sites that
could be expected to be polymorphic in the
subjects from Sonora. These catalogs of sites
served as the basis for the selection of polymor-
phic sites to test for genetic association with
urinary arsenic metabolite proﬁles. The ﬁnal
set of polymorphic sites selected for genetic
association testing consisted of a total of
23 polymorphic sites, 5 in GSTO, 8 in PNP,
and 10 in CYT19.
Genotyping results. DNA from 139 sub-
jects was genotyped at the 23 selected sites.
Initial analyses of the data involved examining
the call rate on a site and a sample basis. Four
DNA samples were excluded from association
analysis because they failed to generate geno-
types for at least 6 of the 23 sites tested.
Within the remaining 135 subjects, genotype
assignment rates for all sites were acceptable,
with nonassignment (individual reactions in
which genotypes could not be called) rates for
the 23 sites ranging from 0 to 5.2%, with a
mean ± SD of 2.0 ± 1.5%. No sites demon-
strated statistically signiﬁcant deviation from
Hardy-Weinberg equilibrium. In addition to
the 135 samples from the Sonoran subjects,
the 22 EA samples used in the initial rese-
quencing project that initially identified all
polymorphic sites were used in all genotyping
assays to allow a check of concordance. All
Taqman assays were completely concordant
with resequencing data. All resequencing-
derived genotypes scored in the genotyping
phase were completely concordant with the
genotypes that were assigned in the initial
resequencing of the genes.
Genetic association analysis. Table 1
summarizes characteristics, including urinary
arsenic species distributions, of the study sub-
jects. The results of the screening of these three
genes for association with the 3:5 and D:M
phenotypes are shown in Table 2. Testing of
differences of means between the genotype
groups for 3:5 used the Mann-Whitney and
Wilcoxon tests because the log-transformed
data did not conform to a normal distribution.
Testing of means in the D:M variable used
two-tailed t-tests. After Bonferroni correction
was applied for 46 tests, three polymorphic
sites in CYT19 (2393, 7388, and 3058) were
signiﬁcantly associated with D:M levels in this
population. To further characterize the associa-
tion between CYT19 DNA sequence and uri-
nary D:M ratio, we tested the influence of
three literature-validated potential covariates
with D:M ratio, age, sex, and daily arsenic
dose, together with the genotype at site 30585,
which had the strongest association with D:M
ratio (Chowdhury et al. 2003; Hopenhayn-
Rich et al. 1996a, 1996b). This characteriza-
tion was performed using a stepwise linear
regression model, incorporating log-converted
D:M ratio as the dependent variable, and
CYT19 30585 genotype, age, sex, and log-
converted daily arsenic dose (micrograms
arsenic per kilogram body weight) as indepen-
dent variables. In the ﬁnal model, the only fac-
tors included were CYT19 30585 genotype
and age, both of which were highly signiﬁcant
(p < 0.001; data not shown). We then re-
examined the data in light of the strong effect
of age on the relationship between CYT19
genotype and D:M ratio. The distribution of
age in this population consisted of a distinct
group of children (n = 45) whose age ranged
from 7 to 11 years. A second group consisted
of adults whose ages ranged from 18 to
79 years. Given our observation of a strong age
and genotype effect in D:M values, as well as
studies that have reported that arsenic metabo-
lism as measured by D:M ratio may be develop-
mentally regulated, we stratiﬁed the population
into children and adults, and tested the CYT19
genetic association with D:M ratio separately
within each group. Figure 2 shows plots of the
95% confidence intervals (CIs) of the mean
log-converted D:M ratio by genotype, together
with the signiﬁcance values for t-tests compar-
ing the genotype-grouped means, for the three
CYT19 polymorphic sites, analyzed separately
for adults and children. Although no statisti-
cally signiﬁcant genetic association is seen in
adults, a highly signiﬁcant genetic association
is observed in children. Using a univariate
general linear model approach to evaluate the
significance of the difference between the
response of children and adults, we tested age
(as a dichotomous variable, child, or adult)
and CYT19 30585 genotype as fixed factors
against D:M ratio as a dependent variable.
The interaction term between age and CYT19
site 30585 genotype was highly significant
(p = 0.0004, unadjusted for multiple compar-
isons), suggesting that the effect of CYT19
genotype at site 30585 relative to D:M value is
different in children from that in adults. As
indicated above, the parents of the children
were removed from the adult group to allow
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Table 1. Characteristics of and urinary arsenic species distribution [µg/L; geometric mean (95% CI)] within
all subjects.
No. Percent male Age As(III) As(V) MMA(V) DMA(V)
Adult 90 29 38.6 7.4 (5.9–9.3) 1.6 (1.4–4.9) 3.6 (3.1–4.2) 22.6 (19.7–25.9)
Child 46 56 9.1 6.3 (4.4–9.2) 1.7 (1.4–2.0) 2.1 (1.5–2.7) 20.7 (15.8–27.0)
Figure 1. Summary of frequency and gene context
of polymorphisms discovered in CYT19 in EA
(Europe) and IA (America) ancestry subjects. ID
column indicates the polymorphism identification
number relative to the location in the consensus
sequence, with the first base of the consensus
numbered 1. ATG offset column indicates the poly-
morphism location relative to the first base “A”
of the ATG methionine initiation codon. Freq %
columns are the minor allele frequency, graphically
displayed in the column to the right. SNP, single
nucleotide polymorphism.
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amino acid substitutions, e.g., M287Tstatistical testing that assumes sample inde-
pendence. Nevertheless, when the mean D:M
ratio by CYT19 30585 genotype group is
compared only between children and their
parents, a similar child-specific effect of the
variant allele on D:M ratio is observed (data
not shown). Because the D:M phenotype has a
self-evident relationship with the second arsenic
methylation, we created a phenotypic variable
to explore the ﬁrst arsenic methylation step, the
3:M ratio. Figure 3 shows the genetic associa-
tion testing in this phenotype for site 30585,
in which a statistically significant difference
between genotypes is observed in children.
We performed LD and haplotype analysis
to further characterize the occurrence of mul-
tiple polymorphism sites in strong association
with D:M ratio. Pairwise LD analysis demon-
strated that all three CYT19 sites are in sig-
nificant LD, with r2 = 0.56 for sites 2393
and 30585 and r2 = 0.94 for sites 7388 and
30585. Genotypes for each child, for all
10 CYT19 sites, were input into the Gibbs
sampling-based haplotype analysis program
PHASE (Stephens and Donnelly 2003;
Stephens et al. 2001). The haplotypes inferred
from this analysis were ﬁltered to remove any
haplotype predicted to occur on only one
chromosome, because of the low confidence
of these rare predictions. Five haplotypes were
predicted to occur on two or more chromo-
somes. The variant alleles at sites 7388 and
30585 only occur together, and only on one
haplotype. The variant allele at site 2393
occurs on two haplotypes, one of which con-
tains the variant alleles for sites 7388 and
30585.
Discussion
To our knowledge this is the most comprehen-
sive genetic association study of arsenic metabo-
lism to date. We observed an extremely strong
association between the DNA sequence of
CYT19 and D:M ratios, an association that
remained highly signiﬁcant even after conserva-
tive multiple testing correction. This association
was confined to the children in the study.
Although the ﬁnding of a genetically and devel-
opmentally restricted association with arsenic
metabolism was unexpected, the presence of a
developmentally restricted component in the
metabolism of arsenic has been documented
(Chowdhury et al. 2003; Kurttio et al. 1998).
Our observations were consistent with these
reports, in that we observed an overall higher
D:M ratio in children. In the study by Kurttio
et al. (1998), a random effects analysis found a
highly signiﬁcant effect of age within the 7- to
13-year age group on DMA levels in the urine,
with children of this age group having higher
DMA levels. It is noteworthy that in the report
by Chowdhury et al. (2003), a graph depicting
age-specific D:M ratio demonstrates both a
pronounced peak in D:M ratio and consider-
able interindividual variability, within an age
range that is similar to that of the children in
our study. It is possible that genetic variation in
CYT19 also explains the variability of the chil-
dren’s D:M ratio values in that study.
Figure 2 also shows that the allele fre-
quency of the positively associated polymor-
phic sites in CYT19 differed between children
and adults. Despite the fact that among the
23 sites examined no statistically significant
difference in allele frequency between children
and adults was observed (data not shown), it is
possible that the allele frequency difference
between children and adults may reflect real
differences in the extent of admixture between
children and adults. In a preliminary explo-
ration of this, we compared the difference in
allele frequency between EA and IA persons at
each of the 23 polymorphic sites from the
resequencing data against the allele frequency
difference between children and adults from
Mexico at the same sites and found a statisti-
cally signiﬁcant negative correlation (data not
shown), suggesting that a participant selection
bias favored more IA ancestry children, more
EA adults, or both. If this admixture bias is
real, two potential ramiﬁcations relative to our
observation of a child-speciﬁc effect must be
considered. The first is that we have simply
tested a marker for IA background that has
nothing to do with this particular biochemical
process. We feel that this is unlikely, given the
magnitude of the effect and the relatively tight
distribution of D:M ratios for children and
adults within a scenario that would predict
that the children are only marginally more
“indigenous American” than the adults.
Alternatively, admixture bias could possibly
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Table 2. Signiﬁcance (p-values) of two-tailed t-tests
for differences in mean phenotype values between
genotype groups, corrected for multiple testing.
Gene Site D:M ratio
GSTO 1859 NS
GSTO –1242 NS
GSTO 5711 NS
GSTO 8102 NS
GSTO 8147 NS
PNP –1626 NS
PNP –1545 NS
PNP 567 NS
PNP 2934 NS
PNP 3746 NS
PNP 5837 NS
PNP 6760 NS
PNP 7821 NS
CYT19 –400 NS
CYT19 –262 NS
CYT19 49 NS
CYT19 2393 0.024
CYT19 5207 NS
CYT19 7388 0.008
CYT19 7588 NS
CYT19 8597 NS
CYT19 20984 NS
CYT19 30585 0.003
NS, not statistically significant at p < 0.05. The 3:5 ratio
was not signiﬁcant for any gene studied.
Figure 2. D:M ratio, stratiﬁed by genotype and age
group at three CYT19 polymorphic positions in unre-
lated Mexican subjects. Log-transformed D:M ratio
for each group is shown as geometric mean, with
error bars delineating the 95% CI of the geometric
mean values. Genotype groups are depicted on the
abscissa. p-Values (unadjusted for multiple com-
parisons) are from a two-tailed t-test comparing the
geometric means of the genotype groups, and
shown only when p < 0.05. Graphs are presented for
CYT19 sites 2393, 7388, and 30585. 
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Figure 3. 3:M ratio, stratiﬁed by genotype at CYT19
site 30585 in the group of children analyzed in
Figure 2. 3:M ratio for each genotype group is
shown as geometric mean, with error bars delineat-
ing the 95% CI of the geometric mean values.
Genotype groups are depicted on the abscissa.
p-Value (unadjusted for multiple comparisons) =
0.023, two-tailed t-test comparing the geometric
means of the genotype groups.
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TT CT+CCunderlie a different LD structure in the chil-
dren than in the adults. In this scenario the
effect in D:M ratio that we observed would
not be child speciﬁc, but rather an LD-speciﬁc
effect due to our tested markers indirectly
“tagging” for another marker, specifically in
children. Although this scenario is possible,
analysis of the pairwise LD in the existing data
from the Mexican population does not sup-
port larger blocks of LD in the children com-
pared with the adults. Even if child-specific
LD was involved in the child-speciﬁc genetic
association, only the location of the causal
polymorphism would be potentially changed,
not the underlying biologic signiﬁcance of the
genetic association. Although not precluding it,
our data do not provide strong support for an
LD-speciﬁc effect in children. Another poten-
tial confounding factor is the sex distribution
between children, in which there was a similar
fraction of males and females, and the adult
group, which was skewed toward females.
Although it is possible that this could have
biased the results in the adult group away from
a genetic association, we think that the mar-
ginal difference in sex composition between
children and adults is unlikely to explain the
difference between the sizable effect seen in
children and lack of observed effect in adults.
One explanation for the presence of an
overall developmental association to the
phenotype, concurrent with a developmental
association between genotype and phenotype,
is that the same biochemical process is involved
with both observations. If the widely observed
developmental association between age and
D:M ratio is caused by the regulation of
CYT19 expression, and the effect of the
CYT19 polymorphisms that were tested in
this study occurred through modulation of
CYT19 expression, then a developmentally
influenced genetic association would not be
unexpected. Notwithstanding the potential
that these polymorphisms may be important
in adults who are arsenic-exposed under dif-
ferent conditions, this study provides clear
evidence that in children exposed to low doses
of arsenic in drinking water there exist signiﬁ-
cant genetic determinants that are strongly
associated with the distribution of urinary
arsenic metabolites, measured by two vari-
ables, D:M ratio and 3:M ratio. It is reason-
able to generalize this to a genetic association
with altered arsenic metabolism itself in chil-
dren. However, because we did not measure
all known metabolic intermediate species of
arsenic, a more speciﬁc assignment of genetic
association to particular metabolic steps
awaits more detailed studies.
The actual genetic variation or variations
that are the causative source of the phenotypic
difference cannot be determined from the
existing data. The fact that the strength of the
genetic association is proportional to the LD
values with the most highly associated site,
30585, raises the possibility that the source
of the association signal is a cluster of poly-
morphic sites that is marked by site 30585.
Likewise, the fact that the sites with the two
strongest association signals, 7398 and 30585,
perfectly deﬁne a single haplotype (they only
occur together, and only on one haplotype)
suggests that an effect owing to this haplotype
cannot be excluded as the source of the asso-
ciation signal. Ultimately, resequencing the
affected subjects will be required to identify the
set of polymorphisms that was tagged by sites
7398 and 30585 in the association study sub-
jects. A frequent focus of genetic association
studies is nonsynonymous polymorphisms.
Resequencing CYT19 revealed only one non-
synonymous polymorphism, a methionine-to-
threonine substitution at residue 287, located
at genomic site 9456. In both the EA and IA
resequencing populations, this site was in per-
fect LD with CYT19 site 5207, which we
tested; we failed to detect any significant
genetic association with any phenotypes. Thus,
our data do not support altered amino acid
sequence as the cause of the genetic association
between CYT19 and arsenic metabolism.
If, as has been well characterized in the
arsenic toxicology literature, arsenic metabo-
lism can govern the creation and removal of
extremely toxic arsenic species, then these
findings may suggest that a particular subset
of exposed children may have increased
susceptibility to arsenic toxicity by virtue of
metabolism that is skewed toward enhanced
accumulation of toxic species. Furthermore,
the reemergence of arsenic compounds as
contemporary pharmaceutical agents, most
recently in the treatment of cancers, expands
the translational scope of this research to
potentially include human pharmacogenetics
of arsenic-based therapy (Evens et al. 2004;
Raza et al. 2004; Rousselot et al. 2004). In
particular, this study should be considered in
light of the current use of arsenical com-
pounds in the treatment of cancer in children
(Calleja and Warrell 2000; George et al.
2004; Ravindranath et al. 2004).
Conclusion
We report a strong genetic association between
polymorphisms of CYT19 and D:M ratio in
Mexican children but not in Mexican adults.
Because the drinking water concentrations of
arsenic in this study represent a range that
includes a large number of children through-
out the world, including North America as
well as Central and South America, the public
health and regulatory implications of this study
are significant. Follow-up studies should be
directed at replicating this finding and at a
ﬁner dissection of the entire arsenic metabolic
pathway. Ideally, these studies will shed light
on the general applicability of this ﬁnding to
similar situations, as well as those involving dif-
fering exposure levels and differing genetic
backgrounds of exposed individuals.
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